Keen Therapeutics
科因生物
Keen Therapeutics (科因生物) is a biotechnology company founded in September 2020 by Wang Yikai, who serves as its founder and CEO . Wang holds degrees from Peking University and Harvard, and previously worked at WuXi AppTAC's domestic new drug R&D services division before transitioning into venture capital at FreeS Fund, where he invested in the same AI-driven drug discovery space he would later enter as an entrepreneur .
The company operates in AI-enabled pharmaceutical R&D, part of a cohort of FreeS portfolio companies in computational biology that also includes XtalPi and Zhihua Technology . FreeS Fund led Keen Therapeutics' angel round in 2020 . As of early 2022, Li Feng of FreeS characterized the firm as part of a bet that "technology will defeat human experience" in drug development—turning Wang's conviction that new tool platforms and efficiency tools could yield globally competitive Chinese pharmaceutical products into an operating company .
elsewhere's corpus does not contain more recent operational or funding updates on Keen Therapeutics beyond this 2021-2022 period.
AI-generated — may contain errors, please verify.
Coverage
The 6 Questions Young People Care About Most: We Asked 17 Founders | FreeS Fund Youth Festival & Graduation Season Special
Passion and conviction are what carry you through the darkness.
峰瑞资本·How to Invest in Biotech in 2023? | FreeS Research
Data-driven, cross-disciplinary, bearing fruit — the most certain direction amid uncertainty
峰瑞资本·Heading Into the Next Spring Amid Winter: 7 Early-Stage Companies Raise Nearly 600 Million RMB | FreeS Family Funding News · Vol 13
Looking forward to working alongside more outstanding founders.
峰瑞资本·Farewell to a Year of Inflection Points: Will 2022 Be Better? | Li Feng's New Year Outlook
Where the heart leads, steady steps take you far.
峰瑞资本·"There Will Come a Moment When Technology Defeats Human Experience" | A Conversation with FreeS Fund
"There will come a moment when technology surpasses human experience."
峰瑞资本·FreeS Fund Earns Ten Honors from Zero2IPO, PEDaily, ChinaVenture & GEW, CVCRI, ChinaRong360, Wanbang RB, and Lancha Consumer | FreeS Matters
Continuously hiring investors
峰瑞资本·Live at 10 AM Tomorrow | New Opportunities in the Changing Landscape of Drug R&D
See you tomorrow at 10 a.m. sharp.
峰瑞资本·How Should We Think About the Present and Future of Drug R&D? | FreeS Fund Dialogue Vol. 2 — Final 2 Days to Register
What new variables and opportunities are emerging in the drug development industry?
峰瑞资本·FreeS Fund Report 25: Food Investment Through the Lens of China's Dietary Structure
What will we eat in the future?
峰瑞资本·New Opportunities Amid the Great Transformation in Drug R&D | FreeS Fund Dialogue Session 2 Now Open for Registration
Breakthroughs and Acceleration in New Drug R&D
峰瑞资本·Biotech Firms Raise Nearly 4 Billion Yuan, Consumer Companies Land Over 1.4 Billion | FreeS Family Funding Roundup · August
We've also released three short videos this week — follow us to check them out.
峰瑞资本·
